Medicenna Therapeutics Corp. (MDNA.TO)
Toronto · CAD · Healthcare · Biotechnology
CA$0.42 (-1.18%) as of
Key statistics
- Market cap
- 38.77M
- Forward P/E
- -1.83
- EPS (TTM)
- -0.2200
- Dividend yield
- 0.00%
- 52-week range
- 0.3350 – 1.9700
- Beta
- 2.10
- Profit margin
- 0.00%
- Analyst target
- CA$3.20
- Volume
- 42.68k
About Medicenna Therapeutics Corp.
Medicenna Therapeutics Corp., a clinical-stage immunotherapy company, engages in the development and commercialization of Superkines and empowered Superkines for the treatment of cancer, inflammation, and immune-mediated diseases. It develops bizaxofusp, an interleukin- 4 (IL-4) targeted therapy for the treatment of recurrent glioblastoma. The company also develops MDNA11, an interleukin-2 (IL-2) to activate anti-cancer immune cells over immunosuppressive Tregs; and MDNA113, a tumor-targeting and activatable bifunctional anti-PD-1-IL-2 superkine for cancer. In addition, its preclinical products are MDNA209, an IL-2/IL-15 antagonist for autoimmune diseases, such as multiple sclerosis and graft versus host diseases, including transplant rejection; and MDNA413, an IL-4/IL-13 antagonist to inflammatory, asthma, and atopic dermatitis, as well as other allergic diseases. Medicenna Therapeutics Corp. is headquartered in Toronto, Canada.
- Sector
- Healthcare
- Industry
- Biotechnology
- Headquarters
- Toronto, ON, Canada
- Employees
- 15
Financial statements (income statement, balance sheet, cash flow) and an interactive price chart are available on this page with JavaScript enabled.